Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
F167802-100mg | 100mg | In stock | $375.90 | |
F167802-500mg | 500mg | In stock | $1,692.90 | |
F167802-1g | 1g | In stock | $3,045.90 | |
F167802-5g | 5g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $13,705.90 | |
F167802-25g | 25g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $61,673.90 |
Synonyms | G02CX02 | Bimt 17 | DTXSID2063472 | 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one | 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-; BIMT 17; BIMT 17BS; Flibanserin | D02577 | 37J |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Flubanserin is a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist. Flubanserin has a high affinity for human 5-HT1A receptors (Ki = 1 nm), low affinity for 5-HT2A (Ki = 49 nm) and D4 (Ki = 4–24 nm), and negligible affinity for a variety of other n |
Storage Temp | Store at 2-8°C,Argon charged |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | AGONIST, ANTAGONIST |
Mechanism of action | Agonist of 5-HT 1A receptor;Antagonist of 5-HT 2A receptor |
ALogP | 3.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
---|---|
INCHI | InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28) |
InChi Key | PPRRDFIXUUSXRA-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F |
Isomeric SMILES | C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F |
WGK Germany | 3 |
PubChem CID | 6918248 |
Molecular Weight | 390.4 |
ChEMBL Ligand | CHEMBL231068 |
---|---|
PubChem CID | 6918248 |
CAS Registry No. | 167933-07-5 |
DrugBank Ligand | DB04908 |
Wikipedia | Flibanserin |
DrugCentral Ligand | 5022 |
GPCRdb Ligand | flibanserin |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2429021 | Certificate of Analysis | Sep 12, 2022 | F167802 |
B2429022 | Certificate of Analysis | Sep 12, 2022 | F167802 |
D2418046 | Certificate of Analysis | Sep 12, 2022 | F167802 |
G2419024 | Certificate of Analysis | Sep 12, 2022 | F167802 |
I2227401 | Certificate of Analysis | Sep 12, 2022 | F167802 |
I2227402 | Certificate of Analysis | Sep 12, 2022 | F167802 |
I2227403 | Certificate of Analysis | Sep 12, 2022 | F167802 |
I2227404 | Certificate of Analysis | Sep 12, 2022 | F167802 |
I2227478 | Certificate of Analysis | Sep 12, 2022 | F167802 |
Solubility | Insoluble in water; Degree of Solubility in water: 4.312 mg/l 25 °C; Very soluble in Chloroform; Soluble in Acetone; Very slightly soluble in Methanol,Ethanol,Toluene |
---|---|
Sensitivity | Air Sensitive |
Melt Point(°C) | 163 °C |
Pictogram(s) | GHS06, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H301:Toxic if swallowed |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
WGK Germany | 3 |
1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. (2002) Pharmacology of flibanserin.. CNS Drug Rev, 8 (2): (117-42). [PMID:12177684] [10.1021/op500134e] |
2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R. (2003) Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.. Br J Pharmacol, 139 (7): (1281-8). [PMID:12890707] [10.1021/op500134e] |
3. Allers KA, Dremencov E, Ceci A, Flik G, Ferger B, Cremers TI, Ittrich C, Sommer B. (2010) Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study.. J Sex Med, 7 (5): (1757-67). [PMID:20163532] [10.1021/op500134e] |
4. D'Aquila P, Monleon S, Borsini F, Brain P, Willner P. (1997) Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.. Eur J Pharmacol, 340 (2-3): (121-32). [PMID:9537806] [10.1021/op500134e] |